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As pharmacokinetic modifiers, cell penetrating peptides (CPPs) have proven utility for the 
delivery of otherwise impermeable cargoes into the discrete intracellular compartments of 
eukaryotic cells. Methods for the molecular optimisation of CPP sequences can significantly 
increase the performance of novel vectors matched to a specific delivery function. Moreover, 
the “information rich” composition and inherent molecular flexibility of many CPPs can also 
facilitate their interaction with intracellular proteins and other cellular structures. This 
proteomimetic property of CPPs has been exploited in the design of bioportides, bioactive 
CPPs that regulate cellular functions often by binding relatively flat PPI interfaces to achieve 
a dominant negative action. This new biology of CPPs is rapidly gathering momentum 
through the design and synthesis of a bewildering variety of peptides that may be, in whole or 
part, linear, helical, cyclic and/or chimeric in nature. A particular emphasis of contemporary 
CPP-centred drug discovery is the unmet medical need of cancer, though the biomedical 
scope of bioportide applications is impressively broad including cellular signalling and 
reprogramming. We are hopeful that one or more of the fascinating studies described herein 


















These are the words of expectation 
These are the words of success, expectation 
The whole world is large, and whatever it is 
The whole trend is effective 
 
Mark E. Smith, The Fall, Words of Expectation, c. 1983. 
 
 
Cell penetrating peptides (CPPs), mostly cationic sequences of 8-18 amino acids, are a 
remarkable category of biomolecule with proven utility for the intracellular delivery of 
otherwise impermeable cargoes. Indeed, and as reviewed,[1,2] the therapeutic potential of CPP 
vectors as pharmacokinetic modifiers is widely recognised. One particular emphasis of CPPs 
for therapeutic application is human cancer, whence strategies can include the covalent 
complexation of a CPP and a tumour targeting peptide to improve the cell- and tissue-specific 
distribution of anticancer drugs such as doxorubicin and paclitaxel.[3] Alternatively, the CPPs 
HR9 and Pep-1 have been investigated as vectors to promote the cellular uptake of a 
genetically modified nitroreductase for applications in directed enzyme prodrug therapy.[4]  
The efficient CPP-mediated delivery of other proteins, including Cre recombinase  and 
CRISPR associated protein, has obvious potential for genome modification and 
transgenesis.[5] Moreover, the enhanced cellular uptake of nucleic acids, including antisense 
oligonucleotides[6] and small interfering Ribonucleic Acid[7-9], is another particularly 
productive avenue for CPP technologies. Both direct conjugation and non-covalent complex 
formation have been employed to combine peptide vectors and therapeutic nucleotides. There 
is also a bewildering variety of nanoparticulate platforms to which the conjugation of CPPs, 
including octa-arginine (R8)[10] and stearylated penetratin,[11] has improved the 
pharmacokinetic parameters of intracellular uptake, oral bioavailability and penetration into 
3D cancer spheroids.  
 Concurrent with the now numerous applications of CPP vectors, of which only a 
small fraction are alluded to above, there has also been an equally fascinating development of 
bioactive CPPs.[12-13] In the simplest sense, a bioactive CPP is a peptide that has the inherent 
capacity to cross the plasma membrane, reach an intracellular site and modulate some aspect 
of cellular physiology. This particular scientific arena, conveniently located at the interface of 
chemistry and biology, is the major focus of this review. Our objectives are to provide a 
succinct overview of many fascinating contemporary developments and yet provide sufficient 
detail to encourage others to pursue their own CPP-based research strategies. 
One can postulate that a CPP-siRNA conjugate is biologically active, but in such a 
construct the CPP vector sequence is reasonably expected to be entirely inert. Conversely, a 
bioactive CPP, perhaps one that mimics a cationic helix involved in protein-protein 
interactions (PPIs), can not only efficiently enter a cell but could also act by a dominant-
negative mechanism to disrupt a signalling interactome (Figure 1A, D). The term bioportide 
has been employed to describe this sub-set of CPPs[14-15] and this designation will, when 
appropriate, be continued herein. Hence, and very deliberately, this is not a review of 
common CPP vectors, CPP-containing nanoparticles or potential mechanisms of CPP import 
into cells. Instead, one focus is the identification and sources of new CPPs and the 
experimental approaches that can be employed to improve the bioavailability and other 
functional parameters of selected bioportides. Methods to assess the cellular penetration of 
CPPs and to determine their intracellular site of accretion are also discussed, promoting a 
broader appraisal of developments in their biological applications. A paradigm shift away 
from the common view of CPPs solely as pharmacokinetic modifiers towards this new 
biology may accelerate the discovery and development of bioportides as innovative biologics 
and potential therapeutic agents. 
 
2 IDENTIFICATION AND SOURCES OF CPPs AND 
BIOPORTIDES 
 
2.1  PROTEIN-DERIVED SEQUENCES 
 
Key events leading to the discovery of CPPs, beginning in the late 1980’s, are amply 
described in Ülo Langel’s latest volume.[16] These efforts culminated in the identification of 
two now widely employed CPP vectors, namely penetratin (RQIKIWFQNRRMKWKK)[17] 
and Tat (GRKKRRQRRRPPQ),[18]  located within the primary sequences of insect- and 
virally-encoded transcription factors (Figure 1A). Many variations of these sequences have 
proven utility for cargo delivery and it is likely that these polycationic domains enable their 
native proteins to traverse biological membranes and fulfil their biological roles as 
transcriptional activators. There was no obvious rational methodology employed to refine 
either these sequences or many others later identified within human arginine-rich proteins,[19] 
rather more a process of… “if it looks like a CPP it might actually be a CPP”. The now 
expansive CPP research arena might well have developed in a rather different direction if one 
or more of these archetypical protein-derived CPPs had proven to possess a desirable 
biological activity. A pool of 272 proteins from 133 viruses proteins are a collective source of 
2444 potential CPP sequences[20] and a search for bioportides within proteins that regulate 
eye development in planarians[21] also identified several very efficient CPPs including the 
octadecapeptide Djeya1(H-RKLAFRYRRIKELYNSYR-NH2). Toxins, perhaps not 
surprisingly considering their biological functions, are also a convenient source of novel 
CPPs (Figure 1A). Thus, a chimeric combination of a Latarcin 1-derived spider toxin peptide 
(KWRRKLKKLR) with a nuclear localisation sequence from Simian virus T antigen yielded 
a novel CPP LDP-NLS (KWRRKLKKLRPKKKRKV), capable of protein delivery.[22] 
Various linear fragments of crotamine, a cationic antimicrobial toxin polypeptide from the 
rattlesnake C. durissus, including C1 (KQCHKKGGHCFPKEKIC), are also effective CPP 
vectors.[23] Of the many hundreds of CPPs described to date[16] a majority are now mostly 
confined to the annals of history; they provide structural clues useful for the development and 
prediction of more efficient CPP vectors, but many are essentially evolutionary dead-ends. 
 
2.2  CPP PREDICTION AND IN SILICO OPTIMISATION OF NOVEL 
 SEQUENCES 
 
A scientifically rational approach for the identification of potential CPP sequences may be a 
more desirable first step towards CPP and bioportide identification. The publically accessible 
CPPsite 2.0[24] is a repository of ~1850 validated CPP sequences and a valuable source of 
information regarding model systems and the range of cargoes delivered by individual 
sequences. One valid approach toward CPP identification is to employ a computer algorithm 
to highlight CPP sequences within the primary sequences of whole proteins and, most 
especially, within sequences enabling PPIs which often contain one or more cationic 
helices.[25,26] The first application of this approach was described in 2005[27] using expanded 
z-scales of amino acid properties to calculate four QSAR variables. The limits of two of these 
variables, trained by known CPPs, are particularly useful for CPP prediction. The web sites 
CellPPD[28] and SkipCPP-Pred[29] are alternative and freely-accessible platforms which 
employ computational methods to predict and modify CPP sequences.  
It is perhaps no surprise that machine learning, a sub category of artificial 
intelligence, is now being utilised to expand the possibilities for CPP prediction based upon 
parameters including AA composition and other physicochemical properties. As an example, 
Diener and co-workers[30] developed a computational prediction method based upon the 
properties of individual AA s but also including calculations of biochemical parameters such 
as mean charge, hydrophobicity, isoelectric point, water-octanol partition and α-helical 
content. Such an approach enabled the characterisation of multifunctional CPPs, some of 
which also possess DNA-binding and antimicrobial activities.[30]  A similar approach can be 
publically accessed on the webserver C2Pred,[31]  an in silico platform which employs 
machine learning to predict CPPs with a potential accuracy of 83.6%.  
Alternative approaches towards the identification of optimised CPPs are based upon 
the constructions and evaluation of larger CPP libraries. For example, comparative data 
derived from the evaluation of 64 CPP-conjugated phosphorodiamidate morpholino 
oligoneucleotides (PMOs) were used to train a random forest declassifier and so select CPPs 
specific for PMO delivery.[32] The evaluation of seven novel CPP sequences with improved 
kinetics[32] further highlights the tremendous potential of such approaches to identify 
enhanced CPPs and to optimise specific functional parameters such as membrane 
insertion.[33] Synthetic molecular evolution (SME), an iterative process employed to design 
and screen combinatorial libraries exploring the sequence space around known templates, has 
also been applied to hybrid CPPs.[34] The screening of a CPP library containing 8192 
Tat/penentratin hybrid peptides coupled to an 18-residue peptide nucleic acid identified gain 
of function daughter Tat- and penetratin-related sequences. The ability of these CPPs to 
translocate a range of cargoes were one to two orders of magnitude more efficient than their 
parent CPPs.[34] Individually and collectively, these studies illustrate the significant 
advantages that in silico computational methods and/or SME can provide for the 
identification and selection of most appropriate CPP vectors. These developments also hint 
that the same approaches might finally enable the first clinically approved CPP formulation. 
We can reliably anticipate that similar methodologies will also support the positive 




3  MOLECULAR DESIGNS FOR BIOPORTIDES 
 
Monomeric linear peptides, including a majority of known CPP sequences, are mostly 
excellent substrates for peptidases. Thus, whilst CPPs can readily enter monolayers of 
cultured eukaryotic cells within a time scale of minutes, applications in vivo are seriously 
limited by the requirement of peptides to cross multiple biological barriers, achieve an 
effective cellular or tissue distribution and subsequently produce a biological effect in the 
absence of toxicity. One excellent review by Kalafatovic and Giralt[35] summarises a range of 
strategies which can be employed to overcome the pharmacokinetic limitations of linear 
CPPs, including those described below. With more selective regard to bioportides, both 
sychnologic and rhegynologic synthetic strategies (Figure 1B) can be distinguished.[14,25,26] 
The molecular organisation of chimeric peptides is necessarily sychnologic whence distinct 
“domains” can be recognised within extended linear sequences. Cyclisation, a strategy to 
enhance the properties of peptides that bind protein targets in a helical conformation, can be 
applied to any bioportide including proteomimetic polycationic sequences that are 
intrinsically cell penetrant and so essentially rhegnylogic in nature.[14,25,26] 
 
 3.1  CHIMERIC PEPTIDES 
 
A variety of chemically diverse CPPs have been employed in the construction of chimeric 
bioportides. Thus, peptides derived from the endoplasmic reticulum protein 44 (ERp44) 
binding domains of adiponectin and immunoglobulin IgM, exemplified by CPP-WT 
(YGRKKRRQRRRKGTCAGWMA), were synthesised with an ER-targeting Tat-related CPP 
(YGRKKRRQRRR) as an N-terminal extension.[36] Additional examples of the inclusion of 
Tat-related CPPs in chimeric bioportides include the 27 AA Tat-K, combining a short 
sequence derived from the Kinase D-interacting subunit of 220 kDa protein separated from 
Tat by a di-prolyl linker (YGRKKRRQRRRPPNTTTLSNLPTNVRN).[37] TAT-NLS-BLBD-
6 (Tat-NLS-ATDEMIPF)[38] is a trimeric construct consisting of Tat, a nuclear location signal 
(NLS) and a short sequence derived from the ß-catenin/lymphoid enhancer factor-1 binding 
domain. The STAT6-IP bioportide[39] is constructed from another Tat variant sequence 
(YARAAARQARA) as a N-terminal extension of a short 7 AA sequence surrounding 
phosphotyrosine641 of the murine STAT-6 transcription factor.  
 Recently reported penetratin-containing bioportides include CP-d/n-ATF5-S1[40] . 
This remarkably large 67 AA trimeric bioportide includes penetratin at the N-terminus, a 
dominant negative repeat sequence mimicking the DNA binding domain of Activating 
Transcription Factor 5 (ATF5) and a truncated human ATF5 basic leucine zipper domain at 
the C-terminus. RT53[41] is a chimeric bioportide consisting of penetratin in the N-terminal 
covalently coupled to 37 AA sequence spanning the heptad leucine repeat domain of the 
Antiapoptosis Clone 11 protein (AAC-11). 
 The general modular nature of peptides readily facilities the covalent additions of 
homing or targeting peptides within a chimeric construct (Figure 1B). As reviewed,[42,43] both 
natural ligands and novel sequences derived from combinatorial screenings can enhance the 
on-site delivery of both peptides and nanocarriers. Some tumour-targeting peptides, including 
LyP1, exhibit cell penetrating properties. Hence, there is obvious potential to include homing 
peptides within the design of chimeric CPPs for targeted drug delivery and to specifically 







3.2  HELICAL, STAPLED AND CYCLIC PEPTIDES 
 
 
There are many cogent reasons to promote the helicity of CPPs and bioportides. A detailed 
evaluation of helix-stabilised CPPs revealed a positive correlation between helicity and 
cellular uptake.[45] Many proteomimetic bioportides derive from helical domains of proteins, 
particularly the molecular interfaces of PPIs. Indeed, one or more cationic helices are a 
common secondary structure within PPI sites where the abundance of arginine is 
enriched.[25,26] The inclusion of α,α-disubstituted amino acids within the sequence of a linear 
peptides is a common strategy to increase the propensity for helix formation.[26] The 
substitution of Ala with α-Aminoisobutyric acid (Aib), a relatively frequent modification, 
forces peptides to adopt either α- or 310-helical conformations due to the steric influence of 
the α,α-dimethyl groups. Aib might also be substituted for other AAs particularly those with 
similar aliphatic side chains: - Val, Ile and Leu. Aib-rich, helix-stabilised CPPs, alternatively 
termed foldamers, are efficient vectors for the delivery of siRNA.[46] Similarly, chimeric 
CPPs, combining Aib-substituted amphipathic helical peptides with a cyclic RGD-related 
homing sequence at the C-terminal, can deliver anti-luciferase siRNA into human lung 
carcinoma A549 cells.[47] With particular relevance to the development of rhegnylogically-
organised bioportides, peptides in which cationic residues, particularly Arg, are involved in 
both membrane translocation and biological activity, cationic α,α-di-substituted AAs have 
also been developed.[45,48] Thus, CPPs containing helicogenic AAs that are mimetics of both 
lysine (ApiC2NH2) and arginine (ApiC2Gu) are more efficient vectors, able to more effectively 
deliver plasmid DNA, than their native non-helical precursors.[48] A similar tactic to promote 
the helicity of polycationic bioportides could well engender improvements in uptake 
efficiency, in vivo stability and biological efficacy (Figure 1B). 
 The introduction of a chemical staple to maintain a helical peptide conformation can 
be a useful strategy towards the development of bioportides which interact with intracellular 
proteins in a helical conformation. Indeed, when compared with conventional small 
molecular weight drugs, peptides have an increased propensity for the binding of larger 
protein surfaces located within PPIs. Many different chemical modifications have been 
utilised to induce conformational restrictions into linear peptides in an effort to enhance 
cellular uptake, improve proteolytic stability and promote target binding to achieve a 
desirable biological outcome (Figure 1B). 
Predictably, cancer is a predominant target for the development of peptide-based 
therapeutics based upon the highly promising stapled-peptide platform. For example, Dietrich 
and co-workers[49] have reported the development of a cell permeable stapled peptide 
inhibitor that targets the interaction between ß-catenin and T cell factor/lymphoid enhancer-
binding factor transcription factors, crucial elements in Wnt signalling pathways. In this later 
study,[49] the stapled StAx peptide (RRWPRXILDXHVRRVWR), containing an all-
hydrocarbon staple formed by ruthenium-modified olefin metathesis of two α-methyl,α-
alkenyl amino acids (X),[50] was further modified by chimeric extension with an NLS and 
substitution of all six Arg residues with homoarginine.  The resulting NLS-StAx-h,[49]  
exhibits much improved cellular uptake, compared with StAx, and is a selective and efficient 
inhibitor of ß-catenin/transcription factor interactions. Molecular dynamics stimulations of 
peptide-estrogen receptor binding were utilised to optimise the biological properties of a 
stapled peptide inhibitor (SRC-SP4)[51] of estrogen receptor/coactivator interactions.[51,52] The 
resulting peptide, R4K1, (Ac-RRRRKXLHRXLQDS-NH2) contains a side chain to side 
chain olefin crosslink between branched residues (X) designed to more closely mimic the 
hydrophobic AA Ile689 and Leu693 of the I689LXXL693L motif of the steroid receptor 
coactivator 2 (SRC2) protein essential for binding estrogen receptor α. The addition of four 
Arg residues at the N-terminal of R4K1was designed to replicate the common structural 
motifs of amphipathic CPPs and so improve cellular permeability.[52]  
 The biologically active form of trypanothione reductase from Leishmania infantum 
(Li-TryR) is dimeric and, thus, the binding interface of Li-TyrR represents a valid target for 
peptide PPI inhibitors.[53] As prototypic inhibitors of Li-Tyr, libraries of stapled analogues, 
both 9-mer and 13-mer, of a proteomimetic sequence of Li-Tyr spanning the “hotspot” 
residue E436 were evaluated for in vitro activity against Leishmania infantum. In this case, 
amide-bridged peptides were prepared by the introduction of a lactam between Glu and Lys 
side chains with an i,i+4 spacing to stabilise a single helical turn. Chimeric conjugation of Li-
Tyr-derived peptides to both Tat and nona-arginine (R9) CPPs enabled some analogues to 
display potent biological activities in cell culture whilst helix-stabilised examples were more 
resistant to proteases that their linear progenitors.[53]A common theme of these studies[49,52,53] 
is that the identification of stapled peptides with desirable uptake kinetics and biological 
activities will generally require the rigorous screening of a library of related compounds. 
Furthermore, it is certain that neither cytosolic nor nuclear accumulation is an intrinsic 
property of all stapled peptides.[54] Hence, the introduction of a chemical staple may not 
always readily achieve pharmacokinetic and pharmacodynamic advantages above those of 
linear bioportides. 
 The terms stapled and cyclic are often employed to describe peptides with similar 
gross architectures. Herein, the term cyclic is restricted to a description of macrocyclic CPPs 
and bioportides that possess no obvious N- or C-termini (Figure 1B). As expertly 
reviewed,[55] a majority of cyclic peptides violate Lipinski’s Rule of 5 and are accordingly 
unable to permeate cellular membranes. However, the discovery of a family of small, 
amphipathic, highly efficient and metabolically stable cyclic CPPs, exemplified by cyclo(D-
Phe-Nal-Arg-D-Arg-Arg-D-Arg-Gln), Nal = L-2-naphthylalanine, facilitated more recent 
discoveries of cyclic bioportides, active at PPIs, either derived from natural sources or by 
rational design and the screening of combinatorial libraries. Large number bicyclic peptide 
libraries are also a valuable source of new bioportides, including a moderately potent but cell-
permeable inhibitor of oncogenic K-Ras.[56] Finally, it is noteworthy that a comparison[57] of 
the uptake mechanisms of chemically diverse cyclic CPPs, synthesised using native chemical 
ligation of N- and C-termini, revealed that cyclisation generally improved uptake efficiency 
but revealed different structural requirements to promote either glycosaminoglycan (GAG)-
dependent endocytosis or direct membrane translocation. 
 
4 INTRACELLULAR ACCESS AND ACCRETION 
 
 
Historical and contemporary efforts to understanding how CPPs and bioportides gain access 
to the various intracellular compartments of eukaryotic cells are excellently reviewed 
elsewhere [1,2,16,35,58]. It is now established that various energy-dependent endocytotic 
pathways and direct membrane translocation, again in many different guises, may contribute 
to the observed internalisation of CPPs. However, the relevant contribution of these quite 
different mechanisms is a likely consequence of CPP sequence, cargo variety and cell type. In 
terms of the development of bioportides to modify cell biology, the precise mechanism of 
internalisation may be of less significance than the final intracellular site of accretion. 
Confocal analyses of the intracellular fate of chemically-diverse fluorescent CPPs and 
bioportides[59] indicate that peptides do not assume a significant cytosolic concentration but 
are instead accreted within specific sites that can include organelles such as mitochondria, 
endoplasmic reticulum and nuclei (Figure 1C). Moreover, it is possible to fine-tune the 
intracellular distribution of peptides by adding proteomimetic sequences from nuclear pore 
proteins[60] or mitochondria-bound hexokinase II (HKII).[61] This individual intracellular 
distribution of peptides almost certainly results from their differential binding to proteins or 
association with lipid membranes. Unfortunately, the mechanisms by which CPPs are 
trafficked within cells are relatively poorly resolved, neither is it certain whether the 
movement of CPPs across the plasma membrane is a two-way process.  
 
4.1  MECHANISTIC INSIGHTS 
 
 
The interaction of positively-charged peptides with negatively-charged components of the 
outer surface of the plasma membrane may be a common first step to promote their 
internalisation. A fuller appreciation of these processes may also facilitate the computational 
design and optimisation[32,33] of improved CPP vectors and bioportides. The relative 
abundance of negatively-charged GAGs, including heparan sulphates, on the cell surface of 
eukaryotic cells most likely enables a first molecular interaction with some CPPs. Indeed, it is 
known that the relative abundance of GAGs, rather than a specific polysaccharide type, is 
crucial for the translocation of amphipathic CPPs, transportan (TP) and TP10, but not R9 or 
Tat, across giant plasma membrane vesicles.[62] Furthermore, P21 
(KRKKKGKGLGKKRDPCLRKYK), the heparin-binding domain from heparin-binding 
epidermal growth factor, promotes CPP-mediated delivery of enzymes, transcription factors, 
antibodies, nanoparticles and nucleic acids.[63] The improved uptake efficiency of some cyclic 
CPPs and bioportides may likewise be the result of a more favourable interaction with 
GAGs.[57] 
 Additional cell-surface interactions, allowing for multiplex modes of the 
internalisation or arginine-rich CPPs, have been recently reviewed by the Futaki group.[64] 
The same team has also identified syndecan-4 as a receptor for the clathrin-mediated 
endocytosis of octa-arginine (R8).[65] Intriguingly, and certainly reflective of the general 
uncertainty regarding the mechanisms of CPP import, the direct translocation of elevated 
concentrations of R8 into cells occurs at sites of looser lipid packing.[66] 
 
4.2 IMPORT INTO COMPLEX TISSUES 
 
 
An overwhelming majority of studies to analyse the import of peptides into cells have utilised 
monolayers of cultured cells and a CPP-conjugate that includes a reporter, often fluorescein 
or some other fluorescent dye such as tetramethylrhodamine (TAMRA).[16, 24,44] In such 
studies, confocal microscopy is a convenient methodology to determine the intracellular site 
of accretion of CPPs and bioportides and semi-quantitative fluorescent assays also facilitate 
comparison of translocation efficacies. A detailed evaluation of both fluorimetric and mass 
spectrometric methods to determine the internalisation of a double-labelled penetratin 
analogue provided consistent results for which detailed protocols are available.[67]  
 Moreover, it is obvious that, to influence the biology and/or pathology of living 
organisms, bioportides may be required to traverse several biological membranes and 
accumulate within tissues at an appropriate concentration (~1-10 µM) to achieve efficient 
internalisation in the absence of cellular toxicity.[1-3] Towards this goal two reports have 
championed very different systems with which to determine the penetration of fluorescent 
peptides into three-dimensional cellular environments. The first of these[68] determined the 
penetration of fluorescein-CPP conjugates into tumour cell spheroids and explant cultures. 
Intriguingly, CPPs with high uptake activity (e.g. penetratin) were sequestered in the 
peripheral cells of spheroid cultures whilst less active examples (R9 variants) penetrated 
deeper into the tissue. These and other data suggested that the comparative evaluation of  
CPPs in a three-dimensional model may lead to a very different choice of most appropriate 
vector when compared to results obtained in cell monolayers.[68] 
 The planarian Schmidtea mediterranea, a favourite organism to study the processes of 
tissue regeneration and stem cell biology, is also a convenient system in which to determine 
the penetration of fluorescent peptides into complex tissues.[21] Whilst whole specimens are 
opaque, the decapitation of adults promotes a developing mass of differentiating cells, the 
blastema, from which regenerates an entire new head equipped with rudimentary eyes and 
nervous system. This tissue, useful from day 2-5 post surgery, is transparent and highly 
amenable to routine confocal analysis in which TAMRA-conjugated CPP can be observed in 
both epithelial and deeper mesenchymal cells. Since the planarian regeneration process is 
absolutely dependent upon the division and differentiation of totipotent stem cells (neoblasts), 
the same model system represents a viable platform to identify bioportides able to influence 
stem cell biology.[21] 
 
5 BIOLOGICAL DEVELOPMENTS 
 
As indicated by the selected examples included below, the opportunities to exploit the unique 
properties of CPPs and bioportides as biological tools and innovative therapeutics directed to 
intracellular targets are manifold. Thus, it is highly probable that the capacity of bioportides 
to modulate potential drug modalities, significantly intracellular PPIs generally considered 
difficult targets for conventional therapeutics, will exploit the intrinsic target specificity, high 
potency and relative safety of ‘biologics’.[58,69] The chemical remodelling of some of these 
lead compounds into peptidomimetic therapeutics, a strategy commonly applied to overcome 
the often rapid proteolysis of simple peptides, is likewise entirely feasible.[70] Some CPPs 
including pVEC (H-LLIILRRRIRKQAHAHSK-NH2), a juxtamembrane protein segment, 
residues 615-632 from murine vascular endothelial-cadherin,[71]  are known to cross the 
blood-brain barrier to reliably enter the brain parenchyma.[72] Thus, potential bioportide 




As reviewed,[12,73] there is tremendous potential to employ bioportides to target the relatively 
expansive protein domains that enable discrete PPIs within cancer cells. Indeed, the scope of 
these new technologies includes CPP-mediated drug-delivery but also the direct modulation 
of intracellular targets with linear peptides, cyclic macropeptides and peptidomimetics.[12,73] 
As further illustrated below, bioportides can be employed to induce the death of cancer cells 
by apoptosis and to modulate more specific signalling pathways, mediated by PPIs or protein-




Clinically useful peptide therapeutics for human cancers include gonadotrophin-releasing 
hormone (GnRH) agonists, GnRH antagonists and somatostatin agonists, agents acting at cell 
surface receptors.[43] There is also tremendous potential to develop other anticancer peptides 
that can influence intracellular PPIs.[12,40, 43,73] It is no surprise that apoptosis, or programmed 
cell death, is a major therapeutic target in cancer since malignant transformations lead to cell 
populations which display a loss of balance between division and death.[40,74] A major 
challenge is to promote apoptosis in actively dividing cancer cells whilst sparing non-
proliferative cells in a quiescent Go phase.  
 Two very different approaches [41,61] illustrate the complexity of intrinsic apoptotic 
pathways accessible to bioportide technologies in cancer cells. As elaborated,[41] the 
antiapoptosis clone 11 protein (AAC-11) is upregulated in most cancer cells to confer a 
survival advantage.  PPIs with several apoptosis-related proteins utilise the heptad leucine 
zipper repeat region of AAC-11. A chimeric CPP (RT53), spanning the heptad leucine repeat 
region domain of AAC-11 (residues 363–399) with penetratin at the N-terminal, specifically 
induces drug-induced apoptotic cell death in a variety of cancers.[75]  Moreover, RT53 also 
acts to promote cancer cell death, whilst sparing non-malignant cells, with a somewhat 
unexpected mechanism of plasma membrane permeabilisation. In vivo, RT53 inhibited the 
growth of human melanoma xenograft models and mediated anticancer effects in a murine 
tumour vaccination model.[41]  
 The high rate of glycolysis observed in many cancer cells may reflect the 
overexpression and increased activity of mitochondria-bound hexokinase II (HKII).[76] pHK-
PAS (MIASHLLAYFFTELNAGKPILFF-NH2), a sychnologic bioportide combining the N-
terminal 15 AA of HKII with a relatively short CPP, described as  a penetration-accelerating 
segment (GKPILFF),[77] enters cells by a combination of both micropinocytosis and energy-
independent mechanisms.[61] This is a somewhat surprising observation considering the net 
charge of pHK-PAS is just 1.1 at neutral pH. However, pKH-PAS is accreted within 
mitochondria where it dissociates the HKII protein from mitochondrial membranes and 
promotes cytochrome c-dependent intrinsic apoptosis, an effect more pronounced in cancer 
cells compared with noncancerous HEK293 cells.[61]  
 
5.1.2 β-CATENIN AND WNT SIGNALLING 
 
The interaction of Wnt (Wingless and INT-1) protein ligands with membrane-bound Wnt 
receptors regulates the expression of many proteins critically involved in cell proliferation 
and differentiation.[78] As previously reported,[49]  targeting the Wnt signalling pathway is an 
attractive therapeutic option but requires agents able to effectively disrupt discrete PPIs.  
Intrinsic to the common canonical Wnt signalling cascade, β-Catenin serves as a 
transcriptional activator of the TCF (T cell factor)/LEF-1 (lymphoid enhancer factor 1) 
family of DNA binding proteins to transduce signals from the plasma membrane to the 
nucleus.  In an effort to control β-Catenin hyperactivity implicated in the initiation and 
progression of cancer, Grossman and co-authors[50] designed a series of stapled peptides to 
disrupt the interaction of β-Catenin with the helical β-Catenin-binding domains of TCF and 
other proteins. The most active, cell permeable, stapled, Axin (Ax)-derived peptide, aStAx-
35R (acetyl-PEG-RRWPRXILDXHVRRVWR-NH2; PEG is polyethylene glycol, X is a site 
of cross link by olefin metathesis) was found to inhibit the growth of Wnt-dependent cancer 
cells without reducing the growth of cancer cells independent of deregulated Wnt 
signalling.[50] More recently,[49] further improvements have optimised the development of 
NLS-StAx-h (PKKKRKV-PEG-hhWPhXILDXHVhhVWh-NH2), a derivative of aStAx-35R 
with an N-terminal NLS sequence and many Arg residues substituted with homoarginine (h), 
commercially marketed by TOCRIS Bioscience.  
Hsieh and co-workers[38] have described a somewhat similar approach to the 
disruption of β-Catenin-specific PPIs, employing Tat to deliver sequences derived from the 
N-terminal of LEF-1, known to bind β-Catenin, into the nuclei. One such peptide TAT-NLS-
BLBD-6 (YGRKKRRQRRR-RKRRK-ATDEMIPF-NH2) directly interacted with β-Catenin 
to inhibit the growth, invasion, migration and colony formation of breast cancer cells and 
supressed breast tumour growth in nude mice.[38] 
 
5.1.3 ESTROGEN RECPTOR/COACTIVATOR INTERACTIONS 
 
Two related publications[51,52] report the sequential development of a cell-permeable stapled 
peptide inhibitor of an estrogen receptor/coactivator interaction as a potential new class of 
breast cancer therapeutic. As described above, first generation peptides were modified with 
an olefinic staple designed to replace two non-interacting residues and mimic Leu and Ile 
residues within a sequence derived from steroid receptor coactivator 2 (SRC2) which 
interacts with estrogen receptor α (ERα).[52]  As exemplified by SRC2-SP2 (acetyl-
KKXLHRXLQDS-NH2; X is a site of cross link by olefin metathesis), this strategy generated 
helical peptides able to bind ERα and inhibit the interaction of a steroid receptor coactivator 
peptide fragment. Molecular dynamics stimulations were subsequently employed[51] to 
convert this high affinity stapled peptide with poor permeability into a bioportide able to 
access the nucleus of eukaryotic cells. Specifically, an extended sequence of SRC2 was 
modified from KEKHK to RRRRK in an effort to increase cationic charge and add a putative 
NLS to R4K1 (acetyl-RRRRKXLHRXLQDS-NH2).
[51] Significantly, R4K1 represses native 
gene transcription mediated by ERα to inhibit the proliferation of estradiol-stimulated MCF-7 
breast cancer cells.[51]  
 
5.1.4 INHIBITION OF p53 AGGREGATION 
 
Several sequences within the DNA binding domain of p53 are believed to contribute to an 
amyloid adhesive segment and promote p53 aggregation in cell lines.[79,80] The septapeptide 
LTIITLE (p53252-258) forms amyloid-like fibrils and was modified by the inclusion of 
aggregation inhibitors such as Arg and Lys to develop an aggregation inhibitor.[80] The most 
promising sequence (LTRITLE), proven to inhibit peptide aggregation in vitro, was 
chimerically combined with the CPP nona-arginine[81] plus a tripeptide linker from the p53 
sequence (RPI) to generate ReACp53 (RRRRRRRRRRPILTRITLE).[80] ReACp53 penetrates 
primary high-grade serous ovarian carcinoma cells to covert mutant p53 from a punctate to a 
soluble form resembling wild type p53. As a consequence, ReACp53 rescues p53 
transcription to restore apoptosis. Moreover, ReACp53 is well tolerated in vivo and halts the 
progression of and shrinks ovarian tumours bearing aggregation-prone p53.[80] 
 
 
5.2 CELLULAR REPROGRAMMING 
 
As reviewed elsewhere,[82,83] the general utility of CPP vectors has enormous potential to 
contribute to a promising future of regeneration therapy. Transcription factors, proteins that 
rely on both PPIs and protein:DNA interactions to regulate gene expression, are obvious 
targets for bioportide technologies.[13] More specifically, and as described above, a cell-
permeable dominant negative peptide inhibitor of ATF5 (CP-d/n-ATF5-S) triggers apoptosis 
in cancer cells whilst sparing normal cells.[40,84] 
The production of patient-specific human induced pluripotent stem cells (hiPSCs), 
generated by the intracellular delivery of reprogramming factors including transcription 
factors, microRNAs and small molecule inhibitors, is advantageous compared with a similar 
application of embryonic stem cells.[82,83] Kaitsuka and Tomizawa have reported[85] that the 
CPP-mediated transduction of three transcription factors, Pdx1, NeuroD and MafA, into 
mouse and human pluripotent stem cells generates a pancreatic lineage. Most intriguingly, the 
transfection of a variety of CPPs alone, including MPG 
(GALFLGFLGAAGSTMGAWSQPKKKRKV)[86] and chimeric constructs contain Tat- and 
penetratin-related sequences, generated embryonic body-like cell clusters from normal adult 
human fibroblasts.[87] This CPP-mediated conversion of somatic cells into multipotent cells is 
critically dependent upon peptide accretion within the nucleus and may result, at least in part, 
from the CPP-mediated dissociation of histone deacetylase 1 and lysine-specific demethylase 
1 from reprogramming factors to reactivate their expression. Whilst this latter study[87] 
provides a novel approach towards the production and reprogramming of hiPSCs and other 
stem cells, it also illustrates a potential caveat to the development of CPPs and bioportides in 
a clinical setting. Moreover, the same intriguing finding suggests that the distinction between 
inert CPP vectors and bioportides is at best blurred! 
 
5.3 NEW BIOLOGY IN NEW DIRECTIONS 
 
We present here a succinct summary of additional publications which investigate and exploit 
the tremendous biomedical potential of bioportides in their various structural guises (Figure 
1D). Clearly, the broad scope of potential applications of cell permeable bioactive peptides, 
ranging from epigenetic modulation[88] to the blockade of Toll-like receptor (TLR) 
signalling,[89] suggests a very healthy future for such technologies. 
 The protein DPY30 is a histone methyltransferase complex regulatory subunit of the 
SET1/MLL family of H3K4 methyltransferases. Moreover, DPY30, significantly upregulated 
in some Burkitt’s lymphoma samples,[90] enhances the methylation activity of SET1/MLL 
complexes by directly binding a relatively short 14 AA C-terminal segment of the ASH2L 
subunit.[88] A sychnologic bioportide (TAT-HA-ASH2L), combining the CPP Tat with an HA 
epitope tag and ASH2L510-529, bound DPY30 to block its interaction with ASH2L and 
significantly inhibit the growth of MLL-rearranged leukaemia and other haematologic cancer 
cells.[88] A similar sychnologic strategy was employed to generate TIP1,[89] a bioportide 
combining penetratin with a sequence derived from the Toll/interleukin-1 receptor (TIR) 
domain-containing adaptor protein (SHCRVLLI). TIP1 specifically binds the BB loop of the 
TLR4-TIR domain to inhibit multiple TLR signalling pathways and has therapeutic potential 
for the treatment of TLR-mediated autoimmune and inflammatory diseases.[89] 
The expression of Cav3.2 T-type calcium channels is regulated by a molecular 
interaction with the deubiquitinase USP5 which is upregulated in chronic pain conditions.[91] 
To block this interaction, Garcia-Caballero and co-workers[91] developed a sychnologic 
bioportide (TAT-cUBP1-USP5) utilising the Tat CPP to deliver a rather lengthy 35 AA 
peptide mimetic of the cUBP domain of USP5 
(NLWLNLTDGSILCGRRYFDGSGGNNHAVEHYRETG) responsible for binding to 
Cav3.2 channels. TAT-cUBP1-USP5 disrupts the Cav3.2/USP5 interaction to attenuate 
mechanical and thermal hyperalgesia.[91]   
 The BRACA2 tumour suppressor protein plays a major role in the repair of DNA 
double-strand breaks by promoting the loading of RAD51 onto single strand DNA. 
Moreover, a 16 AA sequence derived from the BRC4 repeat motif of BRACA2 
(BRACA21521-1536; LLGFHTASGKKVKIAK) blocks the specific interaction of this tumour 
suppressor protein with RAD51.[92] Chimeric combination of this sequence with nona-
arginine generated a bioportide which confers selective hypersensitivity to poly ADP ribose 
polymerase (PARP) inhibition in cancer cells whilst sparing non-cancerous cells.[92] Finally, 
Dominguez-Berrocal et al.[93] have reported the properties of a series of multi-functional 
sychnologic bioportides designed to block the interaction of TEAD and YAP, two proteins 
involved in the Hippo signalling pathway. As a departure from more common practices, this 
study employed novel poly-lysine-containing CPPs, including NLS18 
(RKRKKKKKWKKWPKKKKLD), to affect the intranuclear delivery of interfering mimetic 
sequences. The study identified NLS18-TEAD (NLS18-RLQLVEFSAFVEPPDAVD), a 
bioportide which displays an apoptotic effect in tumour cell lines by targeting a PPI within 
the cell nucleus.[93]  
  
6 FUTURE PROSPECTS AND CONCLSIONS 
 
For many years we have been privileged to be a part of the gregarious international CPP 
community. The important work of many of the key players in the field, people and teams we 
have spoken to and learnt from on many occasions at numerous symposia, are represented 
herein. And yet this review also indicates that CPPs and bioportides are now a relatively 
common technology utilised in many different laboratories. Many of the studies we have 
detailed employ bioportides, linear, helical or cyclic, to address a scientific question or 
achieve a distinct biological influence upon eukaryotic cell systems. Moreover, the 
unquestionable capacity of bioportides to modulate intracellular PPIs indicates that the scope 
of such studies may be constrained only by the limits of human imagination.  
As documented herein, scientific publications will often conclude that this new 
biology of CPPs has therapeutic potential. Certainly, and as expertly reviewed [58,94,95], the 
exploration of new therapeutic modalities beyond conventional peptide ligands will 
necessarily include CPPs and bioportides. Current progress for CPPs within pre-clinical and 
clinical trials is difficult to precisely judge. Of six CPP-containing formulations listed in 
2019[95], the sequences of two have not been disclosed. Moreover, the relatively early failure 
of many CPP formulations might relate to the common capacity of cationic peptides to 
promote the receptor-independent degranulation of mast cells.[96] Thus, the stark reality is that 
few, if any, of the remarkable achievements documented herein will progress to any medical 
benefit. Despite the many potential advantages,[69,70] neither pharmaceutical companies nor 
major research funding agencies are really too enamoured with peptides and other biologics. 
Small molecular weight drugs, acting at “greasy” extracellular targets, stubbornly remain at 
the forefront of modern drug discovery programmes. Thus, obtaining the support to progress 
a peptide lead compound into in vivo studies and early-stage trials remains an almost 
impossible task.  
But there is surely some hope for the future? As described above, several 
studies[32,34,93]  allude to the fact that it is possible to identify novel CPP sequences with 
specific functions tailored towards the delivery of a defined cargo into a particular tissue, cell 
or organelle. Whilst we eagerly recognise the historical significance of generic CPPs, 
including Tat, penetratin and the transportans,[16] and acknowledge that such sequences 
remain commonly utilised in the construction of sychnologic bioportides, it may be time for 
the field to adopt a more strategic approach to the selection and optimisation of CPP vectors. 
The identification of CPPs that are one to two orders of magnitude more efficient than Tat 
and penetratin[34] provides evidence that it will be possible to optimise the delivery kinetics of 
clinically-useful peptides targeting intracellular proteins or PPIs. These potential advantages 
are important because the synthesis of sychnologic sequences (Figure 1B) appears to be the 
more common strategy currently adopted towards the identification of bioportides. Whilst 
several different systems have been investigated as a platform to determine CPP import into 
more complex, multi-dimensional cell masses,[21,68] this remains a rather neglected area of 
research. A more detailed understanding of the fate of CPPs in vivo would almost certainly 
have a dramatic influence upon both the optimised design of bioportides and their routes of 
administration. 
As research probes, commonly exogenously applied to monolayers of cultured cells, 
there is seemingly no obvious requirement for linear bioactive peptide sequences to be 
chemically altered. However, progress towards clinical utility will likely require chemical 
modifications to improve both pharmacokinetic and pharmacodynamic parameters.[25,26,55] As 
evidenced by many of the studies summarised herein, no consensus is available to direct such 
modifications which are consistently challenging in a conventional academic environment. 
Drug discovery, of which bioportide technologies is surely a viable component,[58,94,95] could 
and should be markedly accelerated if governments, pharmaceutical companies and funding 
agencies were challenged to work with academics to more freely provide financial support 
and expertise in drug optimisation and formulation. Perhaps then one or more of the 
bioportide sequences alluded to herein might progress into the clinic to exploit fully this 
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Legend to Figure 1. 
 
FIGURE 1  With a focus upon bioactive CPPs, this review presents common sources of 
CPPs (A), strategies for their molecular design (B) and mechanisms to study CPP import and 
intracellular accretion (C). Finally, we detail examples of the new biology of bioactive CPPs 
or bioportides (D). Figure 1A: Sources of protein-derived cell penetrant sequences; in 
addition to transcription factors and toxins, a common foundation of bioactive CPPs has been 
the protein-protein interaction (PPI) interface, in particular those sequences which correspond 
to cationic helical domains. Figure 1B: Molecular designs; modifications to enhance both 
pharmacokinetic and pharmacodynamic properties of bioactive CPPs include cyclisation, 
hydrocarbon stapling and incorporation of helix promotors such as -aminoisobutyric acid. 
Chimeric bioportides; sequences which correspond to a PPI interface can be rendered 
penetrable by incorporation of a “biologically inert” CPP. This sychnologic organisation 
comprises a chimeric construct whereby the pharmacophores for penetration and bioactivity 
are distinct within the peptide chain.  Alternatively, a molecular architecture that confers both 
membrane translocation and biological activity is typified by a rhegnylogic design, whereby 
the pharmacophores for cellular penetration and bioactivity are discontinuously arranged 
within a linear sequence. Such sequences are often derived from prediction algorithms which 
locate probable penetrant sequences within PPIs or entire proteins. In this conceptual 
diagram, the pharmacophores responsible for cellular penetration (e.g. Arg and Lys) are 
illustrated in black, whereas those conferring bioactivity are shown in blue. The modular 
nature of peptide design further enables the incorporation of a homing peptide or targeting 
moiety so as to ensure tissue-, cellular-, organelle- or protein-specificity. Figure 1C: 
Following membrane translocation, bioactive CPPs accrete within specific intracellular sites 
such as mitochondria, endoplasmic reticulum, nuclei, vesicles and proteins. Figure 1D: With 
specific emphasis on the perturbation of PPIs and protein-DNA interactions, a selection of the 
latest developments in signalling targets for potential human therapies and cellular 
reprogramming are highlighted. 
 
 
